Sarcoma Trials
List of key sarcoma trials
Study Summaries
GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma
Adjuvant chemotherapy with gemcitabine plus docetaxel followed by doxorubicin does not show superior outcomes compared to observation for high-grade uterine leiomyosarcoma.
GeDDiS Trial: Gemcitabine and docetaxel versus doxorubicin as first-line treatment sarcomas
Doxorubicin remains the standard first-line treatment for most patients with advanced soft-tissue sarcoma, as gemcitabine and docetaxel did not demonstrate superiority in survival outcomes
LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma
The combination of doxorubicin and trabectedin significantly improves progression-free survival compared to doxorubicin alone for the first-line treatment of metastatic or unresectable leiomyosarcoma, with an acceptable safety profile despite increased toxicity.
GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
PORTEC 3: Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial cancer
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3):
final results of an international, open-label, multicentre,
randomised, phase 3 trial
CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol
CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol
NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
NRG-GY012
DESKTOP Trial - Secondary Debulking Surgery
Secondary debulking surgery in recurrent ovarian cancer
PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk
Vaginal Brachytherapy vs. Pelvic External Beam Radiotherapy in Endometrial Cancer (PORTEC-2)